Global Hormonal Contraceptive Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global hormonal contraceptive market size reached US$ 17.9 Billion in 2022. Looking forward, the market is expected to reach US$ 22.9 Billion by 2028, exhibiting a growth rate (CAGR) of 4.19% during 2022-2028.

Hormonal contraceptives are formulations of progestin or a combination of estrogen and progesterone hormones. They act on the endocrine system to prevent ovulation and fertilization. As a result, they are used for preventing unwanted pregnancies and are also known to relieve period pain and often result in lighter periods. Hormonal contraceptives are considered one of the most effective methods, which can be taken before and after vaginal intercourse. They include birth control pills, vaginal rings, contraceptive skin patches, and hormone-releasing contraceptive coils. Hormonal contraceptives also affect the womb lining, making it hard for the fertilized eggs to be implanted.

Hormonal Contraceptive Market Trends

The global hormonal contraceptive market is primarily driven by the increasing awareness among the masses regarding family planning. This has facilitated the need to prevent unintended pregnancies, especially among young couples. Furthermore, a significant rise in health issues associated with teenage pregnancies is promoting the use of contraceptives as they are easily accessible. Governments of different countries are also adopting various initiatives to support and improve access to these products by promoting affordable and high-quality healthcare services. Besides this, the advancements in the healthcare industry have resulted in the production of innovative products such as hormonal patches, implants, intrauterine devices, and drug-device combination products. These devices have fewer side effects and enhanced levels of efficiency in preventing pregnancy, which is favorably influencing the growth of the market.

Key Market Segmentation

This research provides an analysis of the key trends in each sub-segment of the global hormonal contraceptive market report, along with forecasts at the global, regional and country level from 2023-2028. The report has categorized the market based on product, hormone, age group and end user.

Breakup by Product:

• Oral Contraceptive Pills
• Intrauterine Device (IUD)
• Injectable Birth Control
• Vaginal Rings

Breakup by Hormone:

• Progestin-only Contraceptive
• Combined Hormonal Contraceptive

Breakup by Age Group:

• 15-24 Years
• 25-34 Years
• 35-44 Years
• Above 44 Years

Breakup by End User:

• Hospitals and Clinics
• Homecare
• Ambulatory Surgical Centers

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Latin America
• Brazil
• Mexico
• Middle East and Africa

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players being Afaxys Inc., Agile Therapeutics Inc., Allergan Inc. (AbbVie Inc.), Bayer AG, Cipla Limited, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Piramal Group and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

• How has the global hormonal contraceptive market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global hormonal contraceptive market?
• What are the key regional markets?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the hormone?
• What is the breakup of the market based on the age group?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global hormonal contraceptive market and who are the key players?
• What is the degree of competition in the industry?